RSRadwa Soliman

Radwa Soliman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Radwa Soliman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patterns of headache in patients with antiphospholipid syndrome in relation to autoantibodies

    by Radwa Soliman, Youssra Gadallah Mahfouz, Rania Gamal Anwar El-Skaan, Warda Abdelfattah Shehata Mohamed

    Background: The interplay between Antiphospholipid syndrome (APS) and migraine is very controversial; migraine is believed to be the most common neurologic symptom in APS, and there are claims that migraineurs have abnormally high Antiphospholipid antibodies (aPL), yet the reports differ widely. Nevertheless, APS could lead to various other types of headaches; both primary and secondary, leaving patients susceptible to exacerbation of symptoms, overlapping of headaches, and atypical presentations. Aim of the work: To describe types and characteristics of headache in a cohort of patients with antiphospholipid syndrome (APS) in comparison to healthy controls. And investigate their possible relation with antiphospholipid antibodies (aPL) and MRI brain findings in patients with APS. Methods: We recruited 76 patients with APS consecutively, between February 2024 and August 2025. From Ain shams university hospital; neurology, internal medicine, and obstetric and gynecology departments, along with 60 matched controls. Patients and controls underwent neurological examination and were evaluated for headache according to the International Headache Society criteria (IHS), Impact and severity were assessed by Migraine Disability Assessment (MIDAS) and Headache Impact Test (HIT). All participants had a brain MRI. Results: A total of 76 patients; 70 females and 6 males, mean age for patients at presentation was 35 ± 8.73 years; mean disease duration was 5 ± 3 years; mean Body mass index (BMI) was 22.38 ± 1.46. Headache was reported by 87% of patients; of which 16 patients suffered secondary type headaches (21%); and 50 patients had primary headaches (65.7%); with migraine being the most common (35%). Anticardiolipin (ACL) antibodies were the most common aPL detected (76.4%) in APS patients. MRI brain was normal in 86% of APS patients with primary headaches, Meanwhile, APS patients with triple positive antibodies showed significantly more abnormal MRI findings ( p = 0.04). Headache severity was significantly more in APS patients ( p = 0.04) Factors affecting headache severity were APS disease duration, BMI, triple aPL positivity ( p =  0.03, 0.00, 0.02 respectively). Conclusion: Primary and secondary types of headaches are frequently reported in Patients with APS, primary headache being more common; migraine in particular. APS patients had significantly more severe headaches. MRI brain was normal in the majority of APS patients with primary headaches and healthy controls. Yet, patients with triple positive antibodies showed more abnormal MRI findings. APS disease duration, BMI, triple aPL were independent factors for headache severity.


  • Open Access

    Mild cognitive impairment and its predictors in patients with Myasthenia Gravis.

    by Yasmin Abd El Hady Mohamed El Mahrouky, Naglaa Mohamed El Khayat, Ahmed Mohamed Hazzou, Radwa Soliman

    Background: Myasthenia gravis (MG) is an autoimmune disorder characterized mainly by muscle weakness with physical exertion. There is conflicting data about the presence of cognitive dysfunction in MG , hence we conducted this study to assess the cognitive functions in patients with MG, and find possible predictors for cognitive impairment in MG patients. Results: A cross-sectional study, where 50 MG patients were recruited consecutively. Patients were diagnosed with MG based on clinical, neurophysiological and laboratorial basis. Their cognitive functions were evaluated via The Arabic Version Montreal Cognitive Assessment (MOCA) and the Arabic Version of Addenbrooke’s Cognitive Examination-III. Moreover, we evaluated patient's Quality of life, Insomnia, and depression via The Arabic version of Myasthenia Gravis Activity Day living (MG-ADL), Insomnia Severity Index (ISI), and the Beck Depression Inventory (BDI) respectively. MG patients had a mean age of 35 ± 12.7 years, majority of patients suffered ocular symptoms (88%). positive ACHR antibody was detected in 80% of patients. MCI was found in 42% of patients, where the visuospatial/executive domains were the most affected. Cognitive impairment correlated with fewer education years, disease duration, severity, elevated AChR antibody titers, and prolonged steroid use. Significant predictors for MCI included bulbar symptoms, MG-ADL score. Conclusion: MCI could be common in patients with MG. Bulbar symptoms, the length of steroid use, the level of ACHR antibodies, disease severity, prolonged duration, insomnia, and depression could contribute to an elevated risk.


  • Translation and validation of the Arabic version of the amyotrophic lateral sclerosis assessment questionnaire (ALSAQ40-AR)

    by Radwa Soliman, Mahmoud S. Swelam, Nagia Fahmy, Hebatallah R. Rashed

    To validate Arabic version of the ALSAQ-40, (ALSAQ40-AR) and assess the QOL in a cohort of Egyptian patients with ALS. This is a prospective study. One hundred consecutive ALS patients were included from the Neuromuscular Unit, Ain Shams University Hospital, in the period from February 2022 to June 2024. Functional and cognitive assessments were done using the Arabic version of ALSFRS-R and ECAS-EG questionnaires, respectively. Disease stage was identified via Kings Clinical Staging. QOL was evaluated using the Arabic WHOQOL-BREF and an Arabic version of ALSAQ-40. ALSAQ40-AR showed high internal consistency using Cronbach's alpha of >0.9, Inter-rater reliability was tested, values for all variables were compared, and no statistically significant differences were found (ICC = .997). Both WHOQOL-BREF and ALSAQ40-AR domains demonstrated significant correlation with each other and with ALSFRS-R (p-value < 0.0001), denoting construct validity. Moreover, ALSAQ40-AR domains correlated significantly with time since disease onset, and showed significant increase across disease stages (p-value < 0.0001). Ceiling and floor effects were analyzed in both QOL scales, but only WHOQOL-BREF showed ceiling and floor effects. ALSAQ40-AR and the WHOQOL-BREF were reliable and valid tools to evaluate QOL in patients with ALS; we suggest that the validated ALSAQ40-AR is more suited for ALS patients because it is a disease specific questionnaire that showed higher internal consistency with no floor or ceiling effects. QOL in ALS was correlated with time since disease onset, disease stage, functional, and cognitive disabilities.

  • Open Access

    Headache types and characteristics in patients with Amyotrophic Lateral Sclerosis

    by Radwa Soliman, Nagia Fahmy, Mahmoud S. Swelam

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive loss of motor neurons, this result in muscle denervation, atrophy and consequently death takes place due to respiratory failure within 3–5 years of onset of symptoms. Was to investigate types and frequency of headache in ALS patients. This is cross sectional hospital based study. Clinically definite 100 ALS Patients (diagnosed according to El Escorial revised criteria) were recruited out of 137 ALS patients presented to the Neuromuscular Clinic in Ain Shams university Hospital from February 2022 to June 2024. Patients were screened for headache types and symptoms diagnosed according to International Headache Society criteria (IHS). Headache severity and impact were assessed using Arabic versions of Headache Impact Test (HIT) and Migraine Disability Assessment (MIDAS). Depression was also assessed via Arabic version of Beck's Depression Inventory (BDI). ALS symptoms severity was assessed via Arabic version of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R). Cognitive functions were assessed via the Egyptian version of the Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS‑EG). Demographic data and ALS related parameters were collected. Among 100 patients with clinically definite ALS, 79 patients reported headaches, 62 of them had primary headaches; with tension-type headache being the most commonly reported in 46 patients, Migraine in 16 patients. Fifteen ALS patients had secondary headaches; among them 12 had headache secondary to respiratory insufficiency and 3 patients developed headache after the initiation of Riluzole therapy. Two patients had non specific headache. Mean age for the patients at ALS presentation was 43.9 ± 13.8, Mean ALSFRS-R score 33.3 ± 9.04. The relationships between headache and clinical features of ALS were also investigated. ALS patients should be evaluated for Headache; Not only headache secondary to respiratory compromise and hypercapnea, but also primary headaches which can be overlooked in patients with ALS.


  • Open Access

    Clinical and epidemiological characteristics of amyotrophic lateral sclerosis in an Egyptian cohort

    by Radwa Soliman, Enass Onbool, Kareem Omran, Nagia Fahmy

    Objective: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive loss of motor neurons. It is a growing and underestimated disease, prompting this epidemiological study to describe the characteristics of ALS in Egyptian patients. Methods: This is a prospective hospital based study. ALS patients were recruited consecutively from Neuromuscular Unit in Ain Shams university Hospital from December 2018 to June 2023. Demographic data and disease related parameters were recorded. Results: 203 ALS patients had a mean age of onset equal 39 years and an inter quartile range IQR of (28.00–51.00). 76% of the cases were spinal onset ALS. Median disease duration was 2 years with IQR of (1–4 years); male to female ratio was 2.5:1; 18% of patients were familial ALS (FALS), while 19% were Juvenile ALS (JALS). Median diagnostic delay was 12 ± (6–36) months. Median Amyotrophic Lateral Sclerosis Functional Rating Scale Revised scores (ALSFRS-R) at presentation was 34.5 IQR of (26.00–40.00). Also, the mean rate of disease progression ALSFRS-R decline [points/month] was 0.76 ± 0.51. Conclusion: Our cohort was characterized by a younger age of onset, male predominance, more familial cases, within average Initial ALSFRS-R scores as well as diagnostic delay. Juvenile ALS patients were much more common in our population. These findings suggest an influential presence of genetic and epigenetic factors affecting the clinical phenotype of Egyptian ALS patients.


  • Open Access

    Cognitive assessment of a sample of Egyptian patients with amyotrophic lateral sclerosis

    by Nourhan Belal, Radwa Soliman, Doha Moustafa ElSerafy, Tarek Okasha, Nagia Fahmy

    Background: Cognitive and behavioral changes in ALS are featured as an integral part of the disease. A noticeable proportion of ALS patients present with a full-blown picture of frontotemporal dementia, which is considered the most common form of cognitive impairment in ALS. Results: A total of 30 ALS cases and 30 sex, age and education matched healthy controls were enrolled; their sociodemographic data were statistically insignificant as regards (age, sex, education). Regarding cognitive and behavioral assessment using the ECAS-EG, both ECAS mean total score and subdomains mean scores were significantly lower in ALS patients compared to controls (p-value < 0.001), with statistically significant relation between ALS clinical staging and ECAS total scores (p-value < 0.001). Furthermore, it was found that mean scores of nearly all ECAS domains are lower in early-onset group with longer duration of illness than late onset with short duration of illness but with a non-statistically significant difference. Conclusion: ALS causes significant cognitive impairment, with relation between functional status and clinical staging of the disease with the severity of cognitive and behavioral dysfunctions and although early-onset cases had lower score on ECAS compared to those with late onset, but it was non-significant.

  • Open Access

    Egyptian adaptation and validation of the Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS-EG)

    by Radwa Soliman, Hebatallah R. Rashed, Ramez R. Moustafa, Nabila Hamdi, Mahmoud S. Swelam, Ahmad Osman, Nagia Fahmy

    Background: Amyotrophic lateral sclerosis (ALS) is the most common, fatal adult neuromuscular disease. It is a multi-system disorder characterized primarily by motor manifestations, but there is established evidence for cognitive and behavioral impairment, which is associated with poor prognosis, hence, the importance of tools for its assessment. The Edinburgh Cognitive and Behavioral Assessment Screen (ECAS) is an invaluable assessment tool for cognition in ALS-front temporal spectrum dementia (FTSD), as it accommodates physical challenges that usually confound traditional neuropsychological testing in those patients. Objective and methods: To validate the Egyptian Arabic version of ECAS (ECAS-EG) based on the original English scale. This is a prospective study. The ECAS was adapted and administered to 62 Egyptian ALS patients and 60 healthy controls. Patients were recruited from the Neuromuscular Unit, Ain Shams University Hospital. The ECAS was adapted to Egyptian Arabic after being translated using the back translation method. Internal consistency of the test, inter-rater reliability, and construct validity were assessed. Results: The Egyptian Arabic version of ECAS (ECAS-EG) showed good internal consistency using Cronbach’s alpha of 0.84. Inter-rater reliability was tested, values for all variables were compared, and no statistically significant differences were found (ICC = .997). ECAS-EG discriminated significantly between the patients from the control subjects (p-value of 0.001). There was a strong positive correlation between the ECAS-EG total score and the MoCA total score with a p-value of 0.001, thus indicating convergent validity. The test showed that 63% of Egyptian ALS patients were cognitively affected; most affected domains were executive functions and verbal fluency. Conclusion: The current study proves that the Egyptian version of the ECAS (ECAS-EG) is valid and reliable among Egyptian ALS patients and it would be applicable to the general Arabic-speaking population.


  • Assessment of diagnostic potential of some circulating microRNAs in Amyotrophic Lateral Sclerosis Patients, an Egyptian study

    by Radwa Soliman, Nahla O. Mousa, Hebatallah R. Rashed, Ramez R. Moustafa, Nabila Hamdi, Ahmad Osman, Nagia Fahmy